Efficacy of cabazitaxel in fourth or later line of therapy in metastatic castration-resistant prostate cancer: Multi-institutional real-world experience in Germany

Contemporary Treatment Patterns and Oncological Outcomes of Metastatic Hormone-sensitive Prostate Cancer and First- to Sixth- line Metastatic Castration-resistant Prostate Cancer Patients

“…This might additionally show that the introduction of new (combination) therapies in mCRPC also leads to longer OS. Comparing the PFS and OS data of more advanced mCRPC treatment lines, a recent multicenter study of cabazitaxel in combined fourth-, fifth-, and sixth-line mCRPC patients observed median PFS and OS of, respectively, 3 and 15 mo [12] . These data are comparable with our results, in which the median OS ranged from 19 mo (fourth-line mCRPC) to 13 mo (sixth-line mCRPC).…”

“…Moreover, it seems that differences in treatment sequences may also affect oncological outcomes [10] . Furthermore, even after receiving multiple therapy lines, mCRPC patients harbor acceptable life expectancy, which might decrease after every therapy line [11] , [12] . However, with the approval of novel treatment options, increasing life expectancy in general, and adoption and improvement of health care systems, trends in systemic mCRPC treatments may differ significantly between more historical and more contemporarily treated mCRPC patients.…”